{"id":4300,"date":"2025-09-27T10:54:08","date_gmt":"2025-09-27T03:54:08","guid":{"rendered":"https:\/\/nhathuocngocanh.com\/bp\/?p=4300"},"modified":"2025-10-02T16:38:58","modified_gmt":"2025-10-02T09:38:58","slug":"bifonazole","status":"publish","type":"post","link":"https:\/\/nhathuocngocanh.com\/bp\/bifonazole\/","title":{"rendered":"Bifonazole"},"content":{"rendered":"

(Ph. Eur. monograph 1395)<\/em><\/p>\n

C22<\/sub>H18<\/sub>N2<\/sub>\u00a0 \u00a0 310.4\u00a0 \u00a0 60628-96-8<\/p>\n

Action and use<\/strong><\/p>\n

Antifungal.<\/p>\n

DEFINITION<\/h2>\n

1-[(RS)-(Biphenyl-4-yl)phenylmethyl]-1H-imidazole.<\/p>\n

Content<\/h3>\n

98.0 per cent to 100.5 per cent (dried substance).<\/p>\n

CHARACTERS<\/h2>\n

Appearance<\/h3>\n

White or almost white, crystalline powder.<\/p>\n

Solubility<\/h3>\n

Practically insoluble in water, sparingly soluble in anhydrous ethanol.<\/p>\n

It shows polymorphism (5.9).<\/p>\n

IDENTIFICATION<\/h2>\n

Infrared absorption spectrophotometry (2.2.24).<\/p>\n

Comparison bifonazole CRS.<\/p>\n

If the spectra obtained in the solid state show differences, dissolve the substance to be examined and the reference substance separately in the minimum volume of 2-propanol R, evaporate to dryness and record new spectra using the residues.<\/p>\n

TESTS<\/h2>\n

Related substances<\/h3>\n

Liquid chromatography (2.2.29).<\/p>\n

Buffer solution pH 3.2 Mix 2.0 mL of phosphoric acid R with 980 mL of water R, adjust to pH 3.2 (2.2.3) with triethylamine R and dilute to 1000.0 mL with water R.<\/p>\n

Test solution: Dissolve 50.0 mg of the substance to be examined in 25 mL of acetonitrile R and dilute to 50.0 mL with buffer solution pH 3.2.<\/p>\n

Reference solution (a): Dilute 1.0 mL of the test solution to 100.0 mL with buffer solution pH 3.2. Dilute 1.0 mL of this solution to 10.0 mL with buffer solution pH 3.2.<\/p>\n

Reference solution (b): Dissolve 2 mg of bifonazole for system suitability CRS (containing impurities A, B, C, D and E) in 2 mL of acetonitrile R and dilute to 10.0 mL with buffer solution pH 3.2.<\/p>\n

Column:<\/p>\n

\u2014 size: l = 0.125 m, \u00d8 = 4.0 mm;<\/p>\n

\u2014 stationary phase: octadecylsilyl silica gel for chromatography R (5 \u03bcm);<\/p>\n

\u2014 temperature: 40 \u00b0C.<\/p>\n

Mobile phase:<\/p>\n

\u2014 mobile phase A: acetonitrile R1, buffer solution pH 3.2 (20:80 V\/V);<\/p>\n

\u2014 mobile phase B: buffer solution pH 3.2, acetonitrile R1 (20:80 V\/V);<\/p>\n\n\n\n\n\n\n
Time<\/strong><\/p>\n

(min)<\/strong><\/td>\n

Mobile phase A<\/strong><\/p>\n

(per cent V\/V)<\/strong><\/td>\n

Mobile phase B<\/strong><\/p>\n

(per cent V\/V)<\/strong><\/td>\n<\/tr>\n

0 – 8<\/td>\n60<\/td>\n40<\/td>\n<\/tr>\n
8 – 12<\/td>\n60 \u2192 10<\/td>\n40 \u2192 90<\/td>\n<\/tr>\n
12 – 30<\/td>\n10<\/td>\n90<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Flow rate: 1 mL\/min.<\/p>\n

Detection: Spectrophotometer at 210 nm.<\/p>\n

Injection: 50 \u03bcL.<\/p>\n

Identification of impurities: Use the chromatogram supplied with bifonazole for system suitability CRS and the chromatogram obtained with reference solution (b) to identify the peaks due to impurities A, B, C, D and E.<\/p>\n

Relative retention: With reference to bifonazole (retention time = about 4 min): impurity C = about 0.2; impurity B = about 0.7; impurity A = about 3.2; impurity D = about 3.6; impurity E = about 5.8.<\/p>\n

System suitability: Reference solution (b):<\/p>\n

\u2014 resolution: minimum 2.5 between the peaks due to impurity B and bifonazole.<\/p>\n

Limits:<\/p>\n

\u2014 correction factor: for the calculation of content, multiply the peak area of impurity C by 2;<\/p>\n

\u2014 impurities B, D: for each impurity, not more than 5 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.5 per cent);<\/p>\n

\u2014 impurities A, C: for each impurity, not more than twice the area of the principal peak in the chromatogram obtained with reference solution (a) (0.2 per cent);<\/p>\n

\u2014 impurity E: not more than 1.5 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.15 per cent);<\/p>\n

\u2014 unspecified impurities: for each impurity, not more than the area of the principal peak in the chromatogram obtained with reference solution (a) (0.10 per cent);<\/p>\n

\u2014 total: not more than 10 times the area of the principal peak in the chromatogram obtained with reference solution (a) (1.0 per cent);<\/p>\n

\u2014 disregard limit: 0.5 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.05 per cent).<\/p>\n

Loss on drying (2.2.32)<\/h3>\n

Maximum 0.5 per cent, determined on 1.000 g by drying in an oven at 105 \u00b0C.<\/p>\n

Sulfated ash (2.4.14)<\/h3>\n

Maximum 0.1 per cent, determined on 1.0 g.<\/p>\n

ASSAY<\/h2>\n

Dissolve 0.250 g in 80 mL of anhydrous acetic acid R. Titrate with 0.1 M perchloric acid, determining the end-point potentiometrically (2.2.20).<\/p>\n

1 mL of 0.1 M perchloric acid is equivalent to 31.04 mg of C22<\/sub>H18<\/sub>N2<\/sub>.<\/p>\n

IMPURITIES<\/h2>\n

Specified impurities A, B, C, D, E.<\/p>\n

\"Bifonazole\"<\/p>\n

A. (RS)-(biphenyl-4-yl)phenylmethanol,<\/p>\n

\"Bifonazole\"<\/p>\n

B. 4-[(RS)-(biphenyl-4-yl)phenylmethyl]-1H-imidazole,<\/p>\n

\"Bifonazole\"<\/p>\n

C. 1H-imidazole,<\/p>\n

\"Bifonazole\"<\/p>\n

D. 1,3-bis[(biphenyl-4-yl)phenylmethyl]-1H-imidazolium ion,<\/p>\n

\"Bifonazole\"<\/p>\n

E. 1,4-bis[(biphenyl-4-yl)phenylmethyl]-1H-imidazole.<\/p>\n","protected":false},"excerpt":{"rendered":"

(Ph. Eur. monograph 1395) C22H18N2\u00a0 \u00a0 310.4\u00a0 \u00a0 60628-96-8 Action and use Antifungal. DEFINITION 1-[(RS)-(Biphenyl-4-yl)phenylmethyl]-1H-imidazole. Content 98.0 per cent to 100.5 per cent (dried substance). CHARACTERS Appearance White or almost white, crystalline powder. Solubility Practically insoluble in water, sparingly soluble in anhydrous ethanol. It shows polymorphism (5.9). IDENTIFICATION Infrared absorption spectrophotometry (2.2.24). Comparison bifonazole CRS….<\/p>\n","protected":false},"author":4,"featured_media":4666,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[174],"tags":[],"class_list":["post-4300","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medicinal-substances"],"acf":[],"_links":{"self":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/4300","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/comments?post=4300"}],"version-history":[{"count":6,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/4300\/revisions"}],"predecessor-version":[{"id":8013,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/4300\/revisions\/8013"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media\/4666"}],"wp:attachment":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media?parent=4300"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/categories?post=4300"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/tags?post=4300"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}